Jeffrey Hung
Stock Analyst at Morgan Stanley
(2.19)
# 2,533
Out of 4,814 analysts
201
Total ratings
34.21%
Success rate
-3.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Holdings | Maintains: Overweight | $37 → $34 | $4.00 | +750.00% | 3 | Mar 11, 2025 | |
| RYTM Rhythm Pharmaceuticals | Assumes: Overweight | $72 | $61.65 | +16.79% | 11 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Assumes: Overweight | $67 → $70 | $47.45 | +47.52% | 11 | Mar 7, 2025 | |
| NBIX Neurocrine Biosciences | Assumes: Overweight | $185 → $150 | $100.10 | +49.85% | 26 | Mar 7, 2025 | |
| JAZZ Jazz Pharmaceuticals | Assumes: Overweight | $175 → $183 | $102.02 | +79.38% | 5 | Mar 7, 2025 | |
| ERAS Erasca | Assumes: Overweight | $4 | $1.16 | +246.32% | 3 | Mar 7, 2025 | |
| IRON Disc Medicine | Assumes: Overweight | $85 | $42.24 | +101.23% | 6 | Mar 7, 2025 | |
| CGEM Cullinan Therapeutics | Assumes: Overweight | $38 → $35 | $7.90 | +343.04% | 6 | Mar 7, 2025 | |
| CTNM Contineum Therapeutics | Assumes: Overweight | $25 | $4.57 | +447.05% | 2 | Mar 7, 2025 | |
| CGON CG Oncology | Assumes: Overweight | $55 | $20.64 | +166.47% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $12.25 | +120.41% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $5 | $3.87 | +29.37% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $20 | $14.71 | +35.96% | 24 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $70 → $67 | $39.48 | +69.71% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $17 → $12 | $6.83 | +75.82% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $9.98 | +250.70% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $70 | $30.40 | +130.26% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $0.84 | +374.38% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $13 → $4 | $1.74 | +129.89% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $0.51 | +684.31% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $60 → $140 | $4.15 | +3,273.49% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $84 | $35.64 | +135.69% | 7 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $40 | $7.35 | +444.22% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $1.25 | +1,020.00% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $1.23 | +308.16% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $0.96 | +211.24% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $1.21 | +1,057.02% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.56 | +543.09% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $36.06 | -38.99% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $20.35 | +629.73% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $1.49 | +3,926.85% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $3.16 | +90.17% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $58 → $54 | $0.34 | +15,876.33% | 6 | May 8, 2020 |
enGene Holdings
Mar 11, 2025
Maintains: Overweight
Price Target: $37 → $34
Current: $4.00
Upside: +750.00%
Rhythm Pharmaceuticals
Mar 7, 2025
Assumes: Overweight
Price Target: $72
Current: $61.65
Upside: +16.79%
PTC Therapeutics
Mar 7, 2025
Assumes: Overweight
Price Target: $67 → $70
Current: $47.45
Upside: +47.52%
Neurocrine Biosciences
Mar 7, 2025
Assumes: Overweight
Price Target: $185 → $150
Current: $100.10
Upside: +49.85%
Jazz Pharmaceuticals
Mar 7, 2025
Assumes: Overweight
Price Target: $175 → $183
Current: $102.02
Upside: +79.38%
Erasca
Mar 7, 2025
Assumes: Overweight
Price Target: $4
Current: $1.16
Upside: +246.32%
Disc Medicine
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $42.24
Upside: +101.23%
Cullinan Therapeutics
Mar 7, 2025
Assumes: Overweight
Price Target: $38 → $35
Current: $7.90
Upside: +343.04%
Contineum Therapeutics
Mar 7, 2025
Assumes: Overweight
Price Target: $25
Current: $4.57
Upside: +447.05%
CG Oncology
Mar 7, 2025
Assumes: Overweight
Price Target: $55
Current: $20.64
Upside: +166.47%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $12.25
Upside: +120.41%
Mar 7, 2025
Assumes: Underweight
Price Target: $5
Current: $3.87
Upside: +29.37%
Mar 7, 2025
Assumes: Equal-Weight
Price Target: $20
Current: $14.71
Upside: +35.96%
Feb 13, 2025
Upgrades: Overweight
Price Target: $70 → $67
Current: $39.48
Upside: +69.71%
Dec 13, 2024
Downgrades: Equal-Weight
Price Target: $17 → $12
Current: $6.83
Upside: +75.82%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $9.98
Upside: +250.70%
May 23, 2024
Maintains: Overweight
Price Target: $50 → $70
Current: $30.40
Upside: +130.26%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $0.84
Upside: +374.38%
Dec 19, 2023
Downgrades: Underweight
Price Target: $13 → $4
Current: $1.74
Upside: +129.89%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $0.51
Upside: +684.31%
Dec 8, 2023
Upgrades: Equal-Weight
Price Target: $60 → $140
Current: $4.15
Upside: +3,273.49%
Nov 3, 2023
Maintains: Overweight
Price Target: $90 → $84
Current: $35.64
Upside: +135.69%
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $7.35
Upside: +444.22%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $1.25
Upside: +1,020.00%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $1.23
Upside: +308.16%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $0.96
Upside: +211.24%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $1.21
Upside: +1,057.02%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.56
Upside: +543.09%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $36.06
Upside: -38.99%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $20.35
Upside: +629.73%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $1.49
Upside: +3,926.85%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $3.16
Upside: +90.17%
May 8, 2020
Maintains: Overweight
Price Target: $58 → $54
Current: $0.34
Upside: +15,876.33%